ID 83826
Title Transcription
ニクガンテキ モンミャク シンシュウ ヨウセイ カンガン セツジョゴ ノ Systemic IFN+Low dose FP ノ ユウヨウセイ : リロンテキ コンキョ ト リンショウテキ コウカ
Title Alternative
Hepatic resection followed by systemic IFN plus low-dose FP for advanced HCC with macroscopic portal invasion : basic background and clinical outcome
Author
Imura, Satoru Department of Digestive Surgery and Transplantation, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Hanaoka, Jun Department of Digestive Surgery and Transplantation, Tokushima University Hospital
Kanamoto, Mami Department of Digestive Surgery and Transplantation, Tokushima University Hospital KAKEN Search Researchers
Mori, Hiroki Department of Digestive Surgery and Transplantation, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ikemoto, Tetsuya Department of Digestive Surgery and Transplantation, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Morine, Yuji Department of Digestive Surgery and Transplantation, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Utsunomiya, Tohru Department of Digestive Surgery and Transplantation, Tokushima University Hospital
Shimada, Mitsuo Department of Digestive Surgery and Transplantation, Tokushima University Hospital Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Keywords
hepatocellular carcinoma
portal vein tumor thrombus
interferon
chemotherapy
Content Type
Journal Article
Description
Background and Aims : Despite a recent progress of treatment for hepatocellular carcinoma (HCC), the prognosis of advanced HCC with macroscopic vascular invasion remains unsatisfactory. We investigated anti-tumor effect of IFNα using experimental model and show the outcome of our systemic adjuvant therapy consisting of IFNα,5FU and cisplatin(IFP)after hepatectomy on advanced HCC with macroscopic portal invasion. Methods[: Basic study]Anti-tumor effects such as inhibition of invasion, proliferation of pegylated IFN α2b(PegIFNα)was evaluated using MH134mouse HCC cells, in vitro and vivo. [Clinical study]: Thirty patients who had HCC with Vp2or more of macroscopic portal invasion(Vp2; portal vein tumor thrombus in its2nd order branch)were included. Those patients were retrospectively divided into two groups : the systemic IFNα,5FU and cisplatin group (n=14, IFP group); and the no adjuvant therapy group(n=16, control). Clinicopathological variables were compared between the two groups, including patient survival and disease-free survival. Results[: Basic]In vitro, the proliferation was significantly suppressed by Peg-IFNα, and invasion potential was also inhibited. In vivo, tumor growth was significantly suppressed compared to control (0.5vs.5.0cm, p<0.05), and liver metastases was decreased(number :19vs.6, p<0.05). [Clinical]The overall and disease-free survival rate in IFP group was significantly higher than in control group(1y :100% vs38%,3y :65% vs25%, P<0.01,1y :36% vs25%,3y :36% vs19%, P<0.01). Regarding the recurrent patterns,5of9patients in IFP group had controllable tumors in the remnant liver, although12of13patients in control group had distant metastasis or multiple recurrences in the residual liver. Conclusion : Our new adjuvant regimen of systemic IFP may be a promising strategy after radical resection for HCC with macroscopic portal invasion.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
67
Issue
3-4
Start Page
147
End Page
154
Sort Key
147
Published Date
2011-08-25
Remark
EDB ID
FullText File
language
jpn
TextVersion
Publisher
departments
University Hospital
Medical Sciences